NuPathe clears new path to US approval of migraine patch with job and cost cuts
This article was originally published in Scrip
Executive Summary
With potential US FDA approval for its first marketed drug on the horizon, NuPathe has disclosed a cost-cutting strategy in documents filed with the US Securities and Exchange Commission (SEC) that includes a 50% workforce reduction and decreased expenditures related to commercialisation of the company's transdermal sumatriptan migraine patch product NP101.